Nomifensine

CAS No. 24526-64-5

Nomifensine( (±)-Nomifensin | NOMIFENSINE MALEATE )

Catalog No. M20731 CAS No. 24526-64-5

Nomifensine is a norepinephrine-dopamine reuptake inhibitor that prevents dopamine reuptake into synaptosomes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 29 In Stock
10MG 29 In Stock
25MG 43 In Stock
50MG 60 In Stock
100MG 99 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Nomifensine
  • Note
    Research use only, not for human use.
  • Brief Description
    Nomifensine is a norepinephrine-dopamine reuptake inhibitor that prevents dopamine reuptake into synaptosomes.
  • Description
    Nomifensine is a norepinephrine-dopamine reuptake inhibitor that prevents dopamine reuptake into synaptosomes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    (±)-Nomifensin | NOMIFENSINE MALEATE
  • Pathway
    GPCR/G Protein
  • Target
    Dopamine Receptor
  • Recptor
    dopamine reuptake
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    24526-64-5
  • Formula Weight
    238.33
  • Molecular Formula
    C16H18N2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:300 mg/mL (1258.76 mM)
  • SMILES
    CN1CC(c2ccccc2)c2cccc(N)c2C1
  • Chemical Name
    8-Isoquinolinamine 1234-tetrahydro-2-methyl-4-phenyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hoffmann I . Pharmacology of Nomifensine[J]. International Pharmacopsychiatry 1982 17(S1):4-20.
molnova catalog
related products
  • Sulpiride

    Sulpiride is a D2 receptor a antagonist, an atypical antipsychotic drug of the benzamide class.

  • Dexpramipexole dihyd...

    A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively.

  • CCT241736

    CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3.